Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 4.69 USD 7.32% Market Closed
Market Cap: 692.2m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptive Biotechnologies Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
EPS (Diluted)
-$1
CAGR 3-Years
1%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
EPS (Diluted)
$15
CAGR 3-Years
-9%
CAGR 5-Years
12%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
EPS (Diluted)
$5
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
EPS (Diluted)
$37
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
13%
Agilent Technologies Inc
NYSE:A
EPS (Diluted)
$4
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
9%
IQVIA Holdings Inc
NYSE:IQV
EPS (Diluted)
$7
CAGR 3-Years
25%
CAGR 5-Years
44%
CAGR 10-Years
11%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
692.1m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.89 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's EPS (Diluted)?
EPS (Diluted)
-1.3 USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's EPS (Diluted) amounts to -1.3 USD.

What is Adaptive Biotechnologies Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-22%

Over the last year, the EPS (Diluted) growth was 1%. The average annual EPS (Diluted) growth rates for Adaptive Biotechnologies Corp have been 1% over the past three years , -22% over the past five years .

Back to Top